Literature DB >> 20571736

[Expression and properties of potassium channels in human mammary epithelial cell line MCF10A and its possible role in proliferation].

Jia Liu1, Shuang Feng, Lei Zhang, Zheng Wu, Qian Chen, Wei Cheng, Shi-Qiang Wang, Wei Zou.   

Abstract

Voltage-dependent potassium channels (Kv) are involved in proliferation and transformation in mammary epithelial cells. In previous studies, several groups have detected various potassium channels in breast cancer cells, and they assumed that potassium channels are related to the development of breast carcinoma, although the precise mechanisms are still unknown. We have previously reported that 4-aminopyridine (4-AP), one kind of potassium channel (K(+) channel) blocker, could affect the proliferation of MCF10A cells. The aim of the present study is to explore the expression and properties of K(+) channels in human mammary epithelial cells (MCF10A) and whether Kv channels are required for the proliferation of MCF10A cell. Electrophysiological, MTT analysis, PCR and Western blot methods were used to identify a K(+) conductance which is involved in tumorigenesis and not yet be described in MCF10A cells. A voltage-dependent, outward rectification and 4-AP-sensitive K(+) current was observed in these cells. The perfusion of 5 mmol/L 4-AP significantly decreased the amplitude of Kv current from (912.5+/-0.6) pA to (275+/-0.8) pA (n=5, P<0.01), when cells were recorded using 800 ms voltage steps from a holding potential of -60 mV to voltage ranging from -60 mV to +60 mV. PCR analysis demonstrated that Kv1.1, Kv1.2, Kv1.3, and Kv1.5 were all expressed in MCF10A and MCF7 cells. Furthermore, the expression of Kv1.5 was much higher in MCF10A than that in MCF7. Inhibitory effect of 4-AP on cell proliferation was dosage-dependent. Incubation with 5 mmol/L 4-AP reduced MCF10A cell proliferation to 25.29% in 48 h. Western blot analysis showed the activation of ERK1/2 which related to cell proliferation was enhanced, while p38 activation was decreased by 4-AP treatment for 10 min. These data provided the first evidence of the Kv channels expression in MCF10A cell and 4-AP could inhibit the proliferation of MCF10A through blocking the potassium channels, and the mechanism may be related to regulating the activity of different members of cell proliferation signaling pathway of MEK/ERK.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20571736

Source DB:  PubMed          Journal:  Sheng Li Xue Bao        ISSN: 0371-0874


  5 in total

1.  Docetaxel modulates the delayed rectifier potassium current (IK) and ATP-sensitive potassium current (IKATP) in human breast cancer cells.

Authors:  Tao Sun; Zhi-Guo Song; Da-Qing Jiang; Hong-Guang Nie; Dong-Yun Han
Journal:  J Membr Biol       Date:  2014-11-25       Impact factor: 1.843

2.  Expression of KCNA5 Protein in Human Mammary Epithelial Cell Line Associated with Caveolin-1.

Authors:  Jia Liu; Chao Qu; Hongyan Li; Yejun Zhang; Jia Sun; Shuo Yang; Jing Liu; Lijia An; Wei Zou
Journal:  J Membr Biol       Date:  2016-04-13       Impact factor: 1.843

3.  Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes.

Authors:  Feifei Su; Miaoqian Shi; Zhiqiang Yan; Dongbo Ou; Juntang Li; Zifan Lu; Qiangsun Zheng
Journal:  Int J Biol Sci       Date:  2012-01-06       Impact factor: 6.580

Review 4.  The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer.

Authors:  Núria Comes; Joanna Bielanska; Albert Vallejo-Gracia; Antonio Serrano-Albarrás; Laura Marruecos; Diana Gómez; Concepció Soler; Enric Condom; Santiago Ramón Y Cajal; Javier Hernández-Losa; Joan C Ferreres; Antonio Felipe
Journal:  Front Physiol       Date:  2013-10-10       Impact factor: 4.566

5.  Caveolin-1 facilitated KCNA5 expression, promoting breast cancer viability.

Authors:  Chao Qu; Jia Sun; Ying Liu; Xiaobo Wang; Lifen Wang; Chao Han; Qian Chen; Tianhui Guan; Hongyan Li; Yejun Zhang; Yang Wang; Jia Liu; Wei Zou; Jing Liu
Journal:  Oncol Lett       Date:  2018-08-03       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.